Case studies

Women’s health native mobile ePRO is an accessible and easy-to-use multi-lingual interface for women who participate in your clinical trials. automated monitoring provides extremely fast detection of protocol deviations and adverse events and has proven to be a key success factor in ensuring high data quality and patient safety in gynecology studies. The combination of native mobile data collection, passive sensors and real-time detection and response enables your clinical operations teams to perform studies on-time and on budget while providing a minimalistic, low-touch user interface for the women in your study.

Gastroenterology customers are successfully executing global multi-center studies in NASH, chronic constipation, AI-driven endoscopy and pre and post-marketing studies of diagnostic devices for Calprotectin, H. pylori, Campylobacter, Rotavirus and E. coli.

A pivotal study for chronic constipation put the unified database to good use by automatically integrating data from connected drugs, native mobile ePRO (in Russian, English, Arabic and Hebrew) and the sponsor EDC system.

Using a small number of heuristic rules the system automates measurement and monitoring of protocol compliance in real-time integrating data streams from patients, sites and drug delivery.

This enables a small 2 person team to manage 100 research sites.


Theranica develops advanced, clinically proven, safe and affordable digital therapeutics, addressing some of the world’s most prevalent neurological pain diseases. We harness a pain inhibition mechanism known as Conditioned Pain Modulation (CPM).

This is the notion that in certain diseases, including migraine, patients have dysfunctional pain processing; a harmless stimulus is perceived by the brain as noxious and the patients experience pain. CPM may be triggered by delivering a remote non-painful but well-felt peripheral stimulus. Once triggered, CPM results with increased release of certain neurotransmitters in the brain stem that are capable of shutting down the pain.

Flaskdata provided Theranica with an integrated continuous clinical data collection and automated monitoring platform.   The continuous data feed ingests data from the EDC, the Nerivio wearable device and patient outcomes via the Theranica mobile app that connects with Flask API.


Flaskdata is at the forefront of providing support for clinical R&D of innovative neuroscience therapies.  The global multi-center clinical trial platform serves companies developing therapeutics for treating depression, OCD and bipolar disorders. The data-driven solution for neuroscience uses the Flask API to integrate clinical data with customer deep learning algorithms in order to improve diagnosis, monitoring and treatment of brain-related disorders.

How to assure adherence in challenging mental health scenarios? helps the neuroscience study team assure patient adherence by providing automated data and safety monitoring tools. Detect and Act algorithms automatically detect dosing anomalies by observing dosing titration trends over time.  Alerts are pushed to the site clinops teams and to sponsor project management in order to provide a same-day response to protocol variations.


Lung cancer remains a leading cause of death from cancer globally, due to its high incidence and late-stage diagnosis. Most patients are currently diagnosed with late-stage cancer, though research has shown 5-year survival rates are up to 10 times greater when disease is detected early. customer Nucleix has developed an ultra-sensitive liquid-biopsy technology for earlier detection of cancer.  Leveraging PCR-based epigenetics, the pioneering Nucleix testing approach uses methylation-based identification for early-stage and recurring cancer detection.

Data-driven solution for oncology provided Nucleix with an EDC platform to perform large-scale data collection of patient medical histories and biomarkers. The data-driven solution for oncology uses the Flask API to integrate clinical data with customer machine learning algorithms in order to train optimal biomarker panels.
An ultra-sensitive, proprietary platform is capable of detecting a single cancer molecule in a background of 200,000 normal molecules.

This ultra-sensitivity enables the Nucleix EpiCheck to detect cancer at its earliest stages when treatment has the greatest impact for patients.

We’re proud to have had the privilege to contribute from our know-how and technology to war on lung and bladder cancer.

Scroll to Top